Gilead Sciences, Inc. (GILD)
151.00
-0.22
(-0.15%)
USD |
NASDAQ |
Sep 04, 16:00
150.90
-0.10
(-0.06%)
After-Hours: 20:00
Gilead Sciences Research and Development Expense (Quarterly) : 1.69B for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.69B |
| March 31, 2026 | 1.354B |
| December 31, 2025 | 1.565B |
| September 30, 2025 | 1.334B |
| June 30, 2025 | 1.45B |
| March 31, 2025 | 1.339B |
| December 31, 2024 | 1.611B |
| September 30, 2024 | 1.385B |
| June 30, 2024 | 1.348B |
| March 31, 2024 | 1.47B |
| December 31, 2023 | 1.515B |
| September 30, 2023 | 1.459B |
| June 30, 2023 | 1.399B |
| March 31, 2023 | 1.45B |
| December 31, 2022 | 1.549B |
| September 30, 2022 | 1.179B |
| June 30, 2022 | 1.102B |
| March 31, 2022 | 1.176B |
| December 31, 2021 | 2.026B |
| September 30, 2021 | 1.147B |
| June 30, 2021 | 1.134B |
| March 31, 2021 | 1.055B |
| December 31, 2020 | 1.512B |
| September 30, 2020 | 1.158B |
| June 30, 2020 | 1.299B |
| Date | Value |
|---|---|
| March 31, 2020 | 1.101B |
| December 31, 2019 | 1.899B |
| September 30, 2019 | 4.99B |
| June 30, 2019 | 1.16B |
| March 31, 2019 | 1.057B |
| December 31, 2018 | 1.13B |
| September 30, 2018 | 939.00M |
| June 30, 2018 | 1.192B |
| March 31, 2018 | 937.00M |
| December 31, 2017 | 978.00M |
| September 30, 2017 | 789.00M |
| June 30, 2017 | 864.00M |
| March 31, 2017 | 931.00M |
| December 31, 2016 | 1.208B |
| September 30, 2016 | 824.00M |
| June 30, 2016 | 1.084B |
| March 31, 2016 | 1.265B |
| December 31, 2015 | 757.00M |
| September 30, 2015 | 744.00M |
| June 30, 2015 | 751.00M |
| March 31, 2015 | 696.00M |
| December 31, 2014 | 1.019B |
| September 30, 2014 | 632.29M |
| June 30, 2014 | 578.64M |
| March 31, 2014 | 592.30M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 993.80M |
| AbbVie, Inc. | 2.344B |
| Regeneron Pharmaceuticals, Inc. | 1.508B |
| Amgen, Inc. | 1.868B |
| Biogen, Inc. | 461.70M |